Loading...
FNCH.Q logo

Finch Therapeutics Group, Inc.OTCPK:FNCH.Q Stock Report

Market Cap US$12.0m
Share Price
US$7.45
My Fair Value
n/a
1Y-42.7%
7D-5.9%
1D
Portfolio Value
​
View

Finch Therapeutics Group, Inc.

OTCPK:FNCH.Q Stock Report

Market Cap: US$12.0m

Finch Therapeutics Group (FNCH.Q) Stock Overview

A clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. More details

FNCH.Q fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Latest financial reports are more than a year old

Highly volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($12M)


FNCH.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Finch Therapeutics Group, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Finch Therapeutics Group
Historical stock prices
Current Share PriceUS$7.45
52 Week HighUS$16.10
52 Week LowUS$2.00
Beta0
1 Month Change-3.25%
3 Month Change-41.89%
1 Year Change-42.69%
3 Year Change-10.02%
5 Year Change-98.30%
Change since IPO-98.84%

Recent News & Updates

Recent updates

Seeking Alpha • Sep 01

Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration

Finch Therapeutics (NASDAQ:FNCH) on Thursday said it planned to cut its workforce by about 37% as part of a strategic review initiated due to Japanese pharmaceutical major Takeda's (NYSE:TAK) decision to discontinue its inflammatory bowel disease (IBD) collaboration with the company. Shares of the micro-cap clinical-stage company fell 7.9% to $1.99 in premarket trading. FNCH last week said it would regain rights to its investigational IBD products FIN-524 and FIN-525 after TAK's decision. FNCH had said it had got more than $44M from the Japanese company over the course of the collaboration. "Following the recent discontinuation of our IBD collaboration with Takeda, coupled with the current capital market environment, we are evaluating our strategy across our entire portfolio and have made the difficult decision to reduce our workforce,” said FNCH CEO Mark Smith in a statement. FNCH on Thursday also said it had decided to stop the initiation of its phase 1 trial of its drug candidate FIN-211 for the treatment of children with autism spectrum disorder.
Seeking Alpha • Aug 25

Finch to get back rights to IBD product candidates after Takeda ends collaboration

Finch Therapeutics Group (NASDAQ:FNCH) on Thursday said Japanese pharmaceutical major Takeda (NYSE:TAK) had ended their collaboration and that it would regain rights to investigational microbiome products FIN-524 and FIN-525. FNCH had signed a development and commercialization deal with TAK for FIN-524 and FIN-525 for the treatment of inflammatory bowel disease (IBD), which would now be terminated effective Nov. 17, Finch (FNCH) said in a statement. FNCH said it had got more than $44M from Takeda (TAK) over the course of the collaboration. Upon termination of the agreement, FNCH will get a royalty-free license to all data and intellectual property generated during the collaboration. FNCH stock -2.1% to $2.63 after hours.
Seeking Alpha • Aug 11

Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M

Finch Therapeutics press release (NASDAQ:FNCH): Q2 GAAP EPS of -$0.48 misses by $0.07. Revenue of $0.36M (-87.3% Y/Y). Finch’s cash and cash equivalents as of June 30, 2022 was $104.7 million, compared to $133.5 million as of December 31, 2021. Shares +1.92% PM.
Analysis Article • Mar 15

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 15

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Aug 28

We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

FNCH.QUS BiotechsUS Market
7D-5.9%-1.6%-0.8%
1Y-42.7%34.4%27.1%

Return vs Industry: FNCH.Q underperformed the US Biotechs industry which returned 34.4% over the past year.

Return vs Market: FNCH.Q underperformed the US Market which returned 27.1% over the past year.

Price Volatility

Is FNCH.Q's price volatile compared to industry and market?
FNCH.Q volatility
FNCH.Q Average Weekly Movement18.2%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Stable Share Price: FNCH.Q's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: FNCH.Q's weekly volatility has increased from 10% to 18% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/aMatt Blischakwww.finchtherapeutics.com

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn’s disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota.

Finch Therapeutics Group, Inc. Fundamentals Summary

How do Finch Therapeutics Group's earnings and revenue compare to its market cap?
FNCH.Q fundamental statistics
Market capUS$11.96m
Earnings (TTM)-US$14.17m
Revenue (TTM)n/a
0.0x
P/S Ratio
0.0x
P/E Ratio

Is FNCH.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FNCH.Q income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$14.17m
Earnings-US$14.17m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did FNCH.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/22 12:37
End of Day Share Price 2026/05/18 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Finch Therapeutics Group, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Maneka MirchandaneyEvercore ISI
Vernon BernardinoH.C. Wainwright & Co.